US Patent Issued to GlaxoSmithKline on March 17 for "Platelet count-agnostic methods of treating myelofibrosis" (Michigan Inventors)

ALEXANDRIA, Va., March 17 -- United States Patent no. 12,576,089, issued on March 17, was assigned to GlaxoSmithKline LLC (Wilmington, Del.).

"Platelet count-agnostic methods of treating myelofibrosis" was invented by Barbara Jane Klencke (Plymouth, Mich.), Gregg David Smith (Plymouth, Mich.) and Rafe Michael Joseph Donahue (Plymouth, Mich.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Reanalysis of the SIMPLIFY 1 and 2 trials data indicates MMB is effective in JAKi-naive patients and in second line therapy to RUX, providing benefits of reducing enlarged spleens, improving myelofibrosis-related symptoms, and increasing transfusion independence in patient at risk for thrombocytopenia from the underlying dise...